With the two active components, sitagliptin and metformin, Janumet has a comprehensive mechanism of action that targets all three key defects of T2DM for improved glycemic control: diminished insulin ...

Sitagliptin, metformin (as HCl) ext-rel; 50mg/500mg, 50mg/1000mg, 100mg/1000mg; tabs. Individualize. Swallow whole. Take once daily with a meal, preferably in the evening. Not currently treated with ...

Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes. Janumet XR is indicated as an adjunct to diet and ...

Lupin has received tentative approval from the Food and Drug Administration for sitagliptin and metformin hydrochloride tablets, 50 mg/500 mg and 50 mg/1000 mg, which is a generic of Merck Sharp & ...

Janumet is indicated in combination with a sulphonylurea i. Janumet is also indicated as add-on to insulin i. The dose of antihyperglycaemic therapy with Janumet should be individualised on the basis ...

The U.S. District Court for the Northern District of West Virginia has ruled in favor of Merck in a patent infringement suit against Viatris related to sitagliptin, an active ingredient in Januvia, ...

Merck’s MRK stock was up 3.5% on Thursday after a U.S. district court ruled in its favor in a patent infringement lawsuit against Viatris VTRS related to sitagliptin. Sitagliptin is the active ...

As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors, by ...